Clinical Trial Update: Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 clinical trial comparing thalidomide 100 mg/day versus 400 mg/day in relapse-refractory multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Thalidomide (thalidomide)

Snippet

Sponsor: Celgene | Conditions: Multiple Myeloma | Phase 2, Phase 3 | Status: COMPLETED